Evidence map›Paper›PMID 37670477›Full record

ArticleCancer communications (London, England)2023

Transcription factor ETV4 promotes the development of hepatocellular carcinoma by driving hepatic TNF-α signaling.

Dandan Qi, Min Lu, Pengfei Xu, Xinli Yao, Yongchen Chen, Lipeng Gan, Yong Li, Yahua Cui, Xiaomei Tong, Shuhong Liu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Association of IL4I1Frontiers in immunology · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Dandan QiKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.
Min LuKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.
Pengfei XuThe Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, P. R. China.
Xinli YaoKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.
Yongchen ChenKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.
Lipeng GanKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.
Yong LiKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.
Yahua CuiSchool of Life Sciences, University of Science and Technology of China, Hefei, Anhui, P. R. China.
Xiaomei TongKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.
Shuhong LiuThe Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, P. R. China.
Jingmin ZhaoThe Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, P. R. China.
Ningning LiuKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.
Xin YeKey Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P. R. China.ORCID 0000-0001-5217-940X
Chinese Academy of Sciences · CNChinese General Hospital College of Nursing and Liberal Arts · PHUniversity of Science and Technology of China · CN

Funding

National Key R&D Program of China 2022YFC2303400National Key R&D Program of China 2022YFC2305205Strategic Priority Research Program of the Chinese Academy of Sciences XDB29010000
6 · The paper itself

Abstract

backgroundHepatic inflammation is the major risk factor of hepatocellular carcinoma (HCC). However, the underlying mechanism by which hepatic inflammation progresses to HCC is poorly understood. This study was designed to investigate the role of ETS translocation variant 4 (ETV4) in linking hepatic inflammation to HCC.

methodsQuantitative real-time PCR and immunoblotting were used to detect the expression of ETV4 in HCC tissues and cell lines. RNA sequencing and luciferase reporter assays were performed to identify the target genes of ETV4. Hepatocyte-specific ETV4-knockout (ETV4

resultsWe revealed that ETV4 was highly expressed in HCC. High levels of ETV4 predicted a poor survival rate of HCC patients. Then we identified ETV4 as a transcription activator of TNF-α and MAPK11. ETV4 was positively correlated with TNF-α and MAPK11 in HCC patients. As expected, an increase in hepatic TNF-α secretion and macrophage accumulation were observed in the livers of ETV4

conclusionsETV4 promoted hepatic inflammation and HCC by activating transcription of TNF-α and MAPK11. Both the ETV4/TNF-α and ETV4/MAPK11 axes represented two potential therapeutic targets for highly associated hepatic inflammation and HCC. ETV4+TNF-α were potential prognostic markers for HCC patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsHumansInflammationMiceProto-Oncogene Proteins c-etsTranscription FactorsTumor Necrosis Factor-alphaETV4 protein, humanProto-Oncogene Proteins c-etsTranscription FactorsTumor Necrosis Factor-alphaETV4hepatic inflammationhepatocellular carcinomamacrophageMAPK11TNF-α

Identifiers

PMID37670477
PMCPMC10693303
OpenAlexW4386467417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.